DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b4vcd4/epicast_report) has announced the addition of the "EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2023" report to their offering.
The epidemiologists forecast that by 2023, there will be approximately 17.38 million total prevalent cases of AD across the 9MM covered in this analysis. The publisher epidemiologists expect a 34.3% increase in the total prevalent cases of AD in the 9MM over the next decade. Similarly, The publisher epidemiologists forecast that the total prevalent cases of MCI in the 9MM will increase from 82.25 million cases in 2013 to 108.41 million cases in 2013 at a decadal growth rate of 31.80%.
- The Alzheimer's disease (AD) EpiCast Report provides an overview of the risk factors and global trends of AD in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, China, and India). The series also includes a 10-year epidemiological forecast for the total prevalent cases of AD segmented by sex, age, and severity in these markets. In addition, the report includes a 10-year epidemiological forecast for the total prevalent cases of mild cognitive impairment (MCI) segmented by sex and age in these markets.
- The AD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.
Key Topics Covered:
1 Tables & Figures
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.2.1 A family history of Alzheimer's increases the risk of developing the disease by 7.5 times
3.2.2 The APOE e4 allele triples the risk for AD
3.2.3 Cardiovascular risk factors in midlife significantly increase the risk of developing AD in later life
3.2.4 The incidence and prevalence of AD double every five years after age 65 years
3.2.5 Diabetes doubles the risk of AD in men, but only marginally affects the risk in women
3.2.6 Women are 1.5 times more likely to develop AD than men
3.2.7 Depression triples the risk for AD, and is the most common comorbidity
3.2.8 Up to 70% of AD patients also suffer from anxiety
3.2.9 Psychosis and agitation are common comorbidities in Alzheimer's patients
3.3 Global Trends
3.4 Forecast Methodology
3.5 Epidemiology Forecast (2013-2023)
For more information visit http://www.researchandmarkets.com/research/b4vcd4/epicast_report